Cardinal Health Inc vs Veritone Inc — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Veritone Inc trades at $1.08 (market cap $98.53M). The key difference: Cardinal Health Inc is far larger — about 546.9× Veritone Inc's market cap, and Cardinal Health Inc pays a 0.89% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| CAH | VERI | |
|---|---|---|
Market Cap | $53.89B | $98.53M |
Sector | Health | Technology |
52-Week High | $239.71 | $8.39 |
52-Week Low | $146.04 | $1.07 |
Enterprise Value | $58.87B | $130.56M |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Veritone (VERI) trades at $1.10, down 6.78% in the last 24 hours, with a bearish technical signal despite oversold RSI readings. The company reported revenue of $92.19 million in 2025 but posted a net loss of $111.73 million, with negative profit margins and cash flow challenges. Recent news highlights multiple class action lawsuits alleging securities fraud, creating significant legal overhangs.
Investment outlook remains highly speculative given persistent losses and legal uncertainties. While analyst consensus shows mixed sentiment with 46% buy ratings, fundamental weaknesses and ongoing litigation pose substantial risks. The stock's current valuation at 0.88x sales offers limited protection against operational challenges and potential legal liabilities.
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →